About Cancer

If cancer has been a chapter in your life or in your family’s history; we, as your personal physicians, will walk this journey with you.

Your 1to1 doctor works in partnership with your oncologist to deliver best outcomes and limit complications before, during, and after oncology care.


Cancer patients are at high risk of serious illness because their immune systems are often weakened by cancer and its treatments. Most people who were treated for cancer in the past (especially if it was years ago) are likely to have normal immune function, but each person is different. It’s important that all cancer patients and survivors, whether currently in treatment or not, talk with a doctor.1

Based on most current data, 1 of every 10 patients who had cancer that was either active or in remission died within 30 days of their coronavirus diagnosis.2 If you have cancer, you are almost 4 times the risk of requiring mechanical ventilation or ICU admission, and 10 times the risk of dying from COVID-19 compared to the general population.2,3,4 Additionally, limited resources in outpatient settings, including access to medical specialties, has hindered the routine care of cancer patients.

As a 1to1 patient, you are not bound to lack of resources. Your 1to1 physician and all possible resources are and will always be available and at your disposal.

The most common symptoms of COVID-19, which may appear 2-14 days after exposure, are: fever of at least 100.4°F (38°C), cough, shortness of breath, chills, muscle aches and pains, sore throat, loss of smell or taste, and gastrointestinal symptoms. Some people with COVID-19 might have signs or symptoms of blood clots such as bluish toes (also referred to as “COVID toes”), swelling of the lower legs, chest pain, or stroke symptoms (slurred speech, weakness or numbness of an arm or leg). Children, in particular, might have fewer symptoms. However, there have been recent reports of children with symptoms such as fever and rash.

If you or your loved ones have been at risk of exposure or experience any of these symptoms, please call your 1to1 concierge doctor to his personal cellphone right away. We will be able to help you.

Tremendous efforts are underway for vaccine development targeting COVID-19.6 However, it may be difficult to illicit a strong immune response in immunocompromised cancer patients.

General public health recommendations to be cautious about:
Earlier in the U.S. outbreak, the CDC and Surgeon General Jerome Adams told everyday Americans to stop buying masks, despite multiple studies demonstrating the airborne capabilities of transmission of the coronavirus.7,8,9

The American Red Cross stated there is no evidence that this new coronavirus can be transmitted through a blood transfusion;10 but an earlier study done in China isolated the virus in different human fluids, including blood.11

Please understand that measures taken
for public health are not individualized care



There are, at least, a dozen COVID vaccines under investigation in late stage clinical trials. Currently, five different vaccine platforms are being used: inactivated, non-replicating viral vector, protein subunit, DNA, and mRNA. The latter platform is a new technology, and has recently received emergency authorization for use in the United States. Note that this does not mean FDA approval, which requires a more stringent process.

Please talk to your 1to1 physician
and ask about which vaccine is best for you



Family history of cancer is one of the biggest predictors of cancer risk. Talk to your 1to1 doctor if you or your family have a history of:

Cancer Types


  • Acute Lymphoblastic Leukemia (ALL)
  • Acute Myeloid Leukemia (AML)
  • Adolescents, Cancer in
  • Adrenocortical Carcinoma
  • AIDS-Related Cancers
    • Kaposi Sarcoma (Soft Tissue Sarcoma)
    • AIDS-Related Lymphoma (Lymphoma)
    • Primary CNS Lymphoma (Lymphoma)
  • Anal Cancer
  • Appendix Cancer
  • Astrocytomas, Childhood (Brain Cancer)
  • Atypical Teratoid/Rhabdoid Tumor, Childhood, Central Nervous System (Brain Cancer)


  • Basal Cell Carcinoma of the Skin
  • Bile Duct Cancer
  • Bladder Cancer
  • Bone Cancer (includes Ewing Sarcoma and Osteosarcoma and Malignant Fibrous Histiocytoma)
  • Brain Tumors
  • Breast Cancer
  • Bronchial Tumors (Lung Cancer)
  • Burkitt Lymphoma


  • Carcinoid Tumor (Gastrointestinal)
  • Carcinoma of Unknown Primary
  • Cardiac (Heart) Tumors, Childhood
  • Central Nervous System
    • Atypical Teratoid/Rhabdoid Tumor, Childhood (Brain Cancer)
    • Medulloblastoma and Other CNS Embryonal Tumors, Childhood (Brain Cancer)
    • Germ Cell Tumor, Childhood (Brain Cancer)
    • Primary CNS Lymphoma
  • Cervical Cancer
  • Childhood Cancers
  • Cancers of Childhood, Rare
  • Cholangiocarcinoma
  • Chordoma, Childhood (Bone Cancer)
  • Chronic Lymphocytic Leukemia (CLL)
  • Chronic Myelogenous Leukemia (CML)
  • Chronic Myeloproliferative Neoplasms
  • Colorectal Cancer
  • Craniopharyngioma, Childhood (Brain Cancer)
  • Cutaneous T-Cell Lymphoma


  • Ductal Carcinoma In Situ (DCIS)


  • Embryonal Tumors, Medulloblastoma and Other Central Nervous System, Childhood (Brain Cancer)
  • Endometrial Cancer (Uterine Cancer)
  • Ependymoma, Childhood (Brain Cancer)
  • Esophageal Cancer
  • Esthesioneuroblastoma (Head and Neck Cancer)
  • Ewing Sarcoma (Bone Cancer)
  • Extracranial Germ Cell Tumor, Childhood
  • Extragonadal Germ Cell Tumor
  • Eye Cancer
    • Intraocular Melanoma
    • Retinoblastoma


  • Fallopian Tube Cancer
  • Fibrous Histiocytoma of Bone, Malignant, and Osteosarcoma


  • Gallbladder Cancer
  • Gastric (Stomach) Cancer
  • Gastrointestinal Carcinoid Tumor
  • Gastrointestinal Stromal Tumors (GIST) (Soft Tissue Sarcoma)
  • Germ Cell Tumors
    • Childhood Central Nervous System Germ Cell Tumors (Brain Cancer)
    • Childhood Extracranial Germ Cell Tumors
    • Extragonadal Germ Cell Tumors
    • Ovarian Germ Cell Tumors
    • Testicular Cancer
  • Gestational Trophoblastic Disease


  • Hairy Cell Leukemia
  • Head and Neck Cancer
  • Heart Tumors, Childhood
  • Hepatocellular (Liver) Cancer
  • Histiocytosis, Langerhans Cell
  • Hodgkin Lymphoma
  • Hypopharyngeal Cancer (Head and Neck Cancer)


  • Intraocular Melanoma
  • Islet Cell Tumors, Pancreatic Neuroendocrine Tumors


  • Kaposi Sarcoma (Soft Tissue Sarcoma)
  • Kidney (Renal Cell) Cancer


  • Langerhans Cell Histiocytosis
  • Laryngeal Cancer (Head and Neck Cancer)
  • Leukemia
  • Lip and Oral Cavity Cancer (Head and Neck Cancer)
  • Liver Cancer
  • Lung Cancer (Non-Small Cell, Small Cell, Pleuropulmonary Blastoma, and Tracheobronchial Tumor)
  • Lymphoma


  • Male Breast Cancer
  • Malignant Fibrous Histiocytoma of Bone and Osteosarcoma
  • Melanoma
  • Melanoma, Intraocular (Eye)
  • Merkel Cell Carcinoma (Skin Cancer)
  • Mesothelioma, Malignant
  • Metastatic Cancer
  • Metastatic Squamous Neck Cancer with Occult Primary (Head and Neck Cancer)
  • Midline Tract Carcinoma With NUT Gene Changes
  • Mouth Cancer (Head and Neck Cancer)
  • Multiple Endocrine Neoplasia Syndromes
  • Multiple Myeloma/Plasma Cell Neoplasms
  • Mycosis Fungoides (Lymphoma)
  • Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
  • Myelogenous Leukemia, Chronic (CML)
  • Myeloid Leukemia, Acute (AML)
  • Myeloproliferative Neoplasms, Chronic


  • Nasal Cavity and Paranasal Sinus Cancer (Head and Neck Cancer)
  • Nasopharyngeal Cancer (Head and Neck Cancer)
  • Neuroblastoma
  • Non-Hodgkin Lymphoma
  • Non-Small Cell Lung Cancer


  • Oral Cancer, Lip and Oral Cavity Cancer and Oropharyngeal Cancer (Head and Neck Cancer)
  • Osteosarcoma and Malignant Fibrous Histiocytoma of Bone
  • Ovarian Cancer


  • Pancreatic Cancer
  • Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)
  • Papillomatosis (Childhood Laryngeal)
  • Paraganglioma
  • Paranasal Sinus and Nasal Cavity Cancer (Head and Neck Cancer)
  • Parathyroid Cancer
  • Penile Cancer
  • Pharyngeal Cancer (Head and Neck Cancer)
  • Pheochromocytoma
  • Pituitary Tumor
  • Plasma Cell Neoplasm/Multiple Myeloma
  • Pleuropulmonary Blastoma (Lung Cancer)
  • Pregnancy and Breast Cancer
  • Primary Central Nervous System (CNS) Lymphoma
  • Primary Peritoneal Cancer
  • Prostate Cancer


  • Rare Cancers of Childhood
  • Rectal Cancer
  • Recurrent Cancer
  • Renal Cell (Kidney) Cancer
  • Retinoblastoma
  • Rhabdomyosarcoma, Childhood (Soft Tissue Sarcoma)


  • Salivary Gland Cancer (Head and Neck Cancer)
  • Sarcoma
    • Childhood Rhabdomyosarcoma (Soft Tissue Sarcoma)
    • Childhood Vascular Tumors (Soft Tissue Sarcoma)
    • Ewing Sarcoma (Bone Cancer)
    • Kaposi Sarcoma (Soft Tissue Sarcoma)
    • Osteosarcoma (Bone Cancer)
    • Soft Tissue Sarcoma
    • Uterine Sarcoma
  • Sézary Syndrome (Lymphoma)
  • Skin Cancer
  • Small Cell Lung Cancer
  • Small Intestine Cancer
  • Soft Tissue Sarcoma
  • Squamous Cell Carcinoma of the Skin
  • Squamous Neck Cancer with Occult Primary, Metastatic (Head and Neck Cancer)
  • Stomach (Gastric) Cancer


  • T-Cell Lymphoma, Cutaneous
  • Testicular Cancer
  • Throat Cancer (Head and Neck Cancer)
    • Nasopharyngeal Cancer
    • Oropharyngeal Cancer
    • Hypopharyngeal Cancer
  • Thymoma and Thymic Carcinoma
  • Thyroid Cancer
  • Tracheobronchial Tumors (Lung Cancer)
  • Transitional Cell Cancer of the Renal Pelvis and Ureter (Kidney (Renal Cell) Cancer)


  • Unknown Primary, Carcinoma of
  • Ureter and Renal Pelvis, Transitional Cell Cancer (Kidney (Renal Cell) Cancer
  • Urethral Cancer
  • Uterine Cancer, Endometrial
  • Uterine Sarcoma


  • Vaginal Cancer
  • Vascular Tumors (Soft Tissue Sarcoma)
  • Vulvar Cancer


  • Wilms Tumor and Other Childhood Kidney Tumors

If you would like further information, please contact us at 1.469.708.9997 or info@1to1.md



1 American Cancer Society -Common Questions About the New Coronavirus Outbreak https://www.cancer.org/latest-news/common-questions-about-the-new-coronavirus-outbreak.html

2 Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020; This was the first study to evaluate cancer patients being at a higher risk of serious illnesses from COVID-19, and rather extra precaution is very much advised for this patient population.

3 Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; Highlights initial stages of COVID-19 was managed in China, and further management steps were utilized globally.

4 Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA2020; available from: 10.1001/jama.2020.4683.

5 Ueda M, Martins R, Hendrie PC, et al. Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal. J Natl Compr Canc Netw. 2020; Highlights briefly important aspects of cancer care within the United States.

6 Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1–9

7 CDC and WHO offer conflicting advice on masks. An expert tells us why. https://www.msn.com/en-us/health/medical/cdc-and-who-offer-conflicting-advice-on-masks-an-expert-tells-us-why/ar-BB14Mys2

8 Olsen SJ, Chang HL, Cheung TY, Tang AF, Fisk TL, Ooi SP, et al. Transmission of the severe acute respiratory syndrome on aircraft. N Engl J Med. 2003;349:2416–2422. doi: 10.1056/NEJMoa031349.

9 Yu IT, Li Y, Wong TW, Tam W, Chan AT, Lee JH, et al. Evidence of airborne transmission of the severe acute respiratory syndrome virus. N Engl J Med. 2004;350:1731–1739. doi: 10.1056/NEJMoa032867.

10 American Cancer Society -Common Questions About the New Coronavirus Outbreak https://www.cancer.org/latest-news/common-questions-about-the-new-coronavirus-outbreak.html

11 Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9(1):386–389. doi: 10.1080/22221751.2020.1729071.